(Q41542192)

English

Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).

scientific article published on 27 July 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 October 2017

Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). (English)

1 reference

Europe PubMed Central

2 October 2017

phase III clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

author name string

M-H Ryu

1

1 reference

Europe PubMed Central

2 October 2017

E Baba

2

1 reference

Europe PubMed Central

2 October 2017

K H Lee

3

1 reference

Europe PubMed Central

2 October 2017

Y I Park

4

1 reference

Europe PubMed Central

2 October 2017

N Boku

5

1 reference

Europe PubMed Central

2 October 2017

I Hyodo

6

1 reference

Europe PubMed Central

2 October 2017

B-H Nam

7

1 reference

Europe PubMed Central

2 October 2017

T Esaki

8

1 reference

Europe PubMed Central

2 October 2017

C Yoo

9

1 reference

Europe PubMed Central

2 October 2017

B-Y Ryoo

10

1 reference

Europe PubMed Central

2 October 2017

E-K Song

11

1 reference

Europe PubMed Central

2 October 2017

S-H Cho

12

1 reference

Europe PubMed Central

2 October 2017

W K Kang

13

1 reference

Europe PubMed Central

2 October 2017

S H Yang

14

1 reference

Europe PubMed Central

2 October 2017

D Y Zang

15

1 reference

Europe PubMed Central

2 October 2017

D B Shin

16

1 reference

Europe PubMed Central

2 October 2017

S R Park

17

1 reference

Europe PubMed Central

2 October 2017

K Shinozaki

18

1 reference

Europe PubMed Central

2 October 2017

T Takano

19

1 reference

Europe PubMed Central

2 October 2017

Y-K Kang

20

1 reference

Europe PubMed Central

2 October 2017

SOS study investigators

21

1 reference

Europe PubMed Central

2 October 2017

publication date

27 July 2015

1 reference

Europe PubMed Central

2 October 2017

Annals of Oncology

1 reference

Europe PubMed Central

2 October 2017

26

1 reference

Europe PubMed Central

2 October 2017

10

1 reference

Europe PubMed Central

2 October 2017

2097-2101

1 reference

Europe PubMed Central

2 October 2017

Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV316

21 January 2018

Identifiers

10.1093/ANNONC/MDV316

1 reference

Europe PubMed Central

2 October 2017

1 reference

Europe PubMed Central

2 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41542192&oldid=1530293652"